N-MOmentum - study design for a placebo-controlled study of MEDI-551 in neuromyelitis optica

被引：0
|
作者：
Cree, B. A. C. [1 ]
Bennett, J. L. [2 ]
Hartung, H. -P. [3 ]
Aktas, O. [3 ]
Kim, H. J. [4 ,5 ]
Paul, F. [6 ]
Pittock, S. [7 ]
Weinshenker, B. [7 ]
Wingerchuk, D. [8 ]
Marignier, R. [9 ]
Fujihara, K. [10 ]
Cutter, G. [11 ]
Flor, A. [12 ]
Barron, G. [13 ]
Patra, K. [12 ]
Madani, S. [12 ]
Katz, E. [13 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Univ Colorado, Denver, CO 80202 USA
[3] Univ Dusseldorf, Dusseldorf, Germany
[4] Res Inst, Seoul, South Korea
[5] Natl Canc Ctr Hosp, Seoul, South Korea
[6] Charite, D-13353 Berlin, Germany
[7] Mayo Clin, Rochester, MN USA
[8] Mayo Clin, Scottsdale, AZ USA
[9] Lyon Univ Hosp, Lyon, France
[10] Tohoku Univ, Sendai, Miyagi 980, Japan
[11] Univ Alabama Birmingham, Birmingham, AL USA
[12] MedImmune, Gaithersburg, MD USA
[13] MedImmune, Cambridge, England
来源：
MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1349
引用
收藏
页码：705 / 706
页数：2
相关论文
共 50 条
  • [31] Aqp4-igg seronegative patient outcomes in the n-momentum trial of inebilizumab in neuromyelitis optica spectrum disorder
    Pittock, S.
    Paul, F.
    Marignier, R.
    Kim, H. J.
    Bennett, J.
    Weinshenker, B.
    Wingerchuk, D.
    Green, A.
    Fujihara, K.
    Cutter, G.
    Aktas, O.
    Hartung, H. P.
    Drappa, J.
    Ratchford, J.
    She, D.
    Cimbora, D.
    Katz, E.
    Cree, B.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 208 - 209
  • [32] AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder
    Marignier, Romain
    Pittock, Sean J.
    Paul, Friedemann
    Kim, Ho Jin
    Bennett, Jeffrey L.
    Weinshenker, Brian G.
    Wingerchuk, Dean M.
    Green, Ari J.
    Fujihara, Kazuo
    Cutter, Gary
    Aktas, Orhan
    Hartung, Hans-Peter
    Drappa, Jorn
    Ratchford, John N.
    She, Dewei
    Smith, Michael
    Rees, William
    Cimbora, Daniel
    Katz, Eliezer
    Cree, Bruce A. C.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 57
  • [33] Characterization of B cell subset changes following treatment of Neuromyelitis Optica Spectrum Disorder with inebilizumab: results from the N-MOmentum study randomized control period
    Bennett, J.
    Aktas, O.
    Rees, W.
    Smith, M.
    del Nagro, C.
    Yan, L.
    Drappa, J.
    Barron, G.
    Madani, S.
    Ratchford, J.
    Shi, D.
    Cimbora, D.
    Pittock, S.
    Weinshenker, B.
    Paul, F.
    Cutter, G.
    Marignier, R.
    Wingerchuk, D.
    Hartung, H. -P.
    Kim, H. J.
    Fujihara, K.
    Katz, E.
    Levy, M.
    Cree, B.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 590 - 592
  • [34] Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study
    Agius, Mark A.
    Klodowska-Duda, Gabriela
    Maciejowski, Maciej
    Potemkowski, Andrzej
    Li, Jing
    Patra, Kaushik
    Wesley, Jacob
    Madani, Soraya
    Barron, Gerard
    Katz, Eliezer
    Flor, Armando
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (02) : 235 - 245
  • [35] The N-MOmentum Trial of Inebilizumab for Neuromyelitis Optica Spectrum Disorder: Long-term, Open-label Efficacy and Safety Update
    Cree, B. A.
    Bennett, J. L.
    Weinshenker, B. G.
    Wingerchuk, D.
    Paul, F.
    Kim, H.
    Pittock, S.
    Fujihara, K.
    Cutter, G.
    Marignier, R.
    Aktas, O.
    Hartung, H.
    Green, A. J.
    Drappa, J.
    She, D.
    Cimbora, D.
    Rees, W.
    Smith, M.
    Ratchford, J. N.
    Katz, E.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (1_SUPPL) : 83 - 83
  • [36] Results of a Phase 2 Study of MEDI-551 and Bendamustine Vs Rituximab and Bendamustine in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Gladstone, Douglas
    Andre, Marc
    Jan Zaucha
    Assouline, Sarit
    Bellam, Naresh
    Cascavilla, Nicole
    Jourdan, Eric
    Panwalkar, Amit
    Patti, Caterina
    Schulte, Clemens
    Zaja, Francesco
    Goswami, Trishna
    Elgeioushi, Nairouz
    Streicher, Katie
    Bao, Haifeng
    Spaner, David
    BLOOD, 2014, 124 (21)
  • [37] Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial
    Tahara, Masayuki
    Oeda, Tomoko
    Okada, Kazumasa
    Kiriyama, Takao
    Ochi, Kazuhide
    Maruyama, Hirofumi
    Fukaura, Hikoaki
    Nomura, Kyoichi
    Shimizu, Yuko
    Mori, Masahiro
    Nakashima, Ichiro
    Misu, Tatsuro
    Umemura, Atsushi
    Yamamoto, Kenji
    Sawada, Hideyuki
    LANCET NEUROLOGY, 2020, 19 (04): : 298 - 306
  • [38] The impact of low affinity immunoglobulin gamma Fc region receptor III-A gene polymorphisms in neuromyelitis optica spectrum disorder and implications for treatment outcomes: results from the N-MOmentum study
    Bennett, J. L.
    Weinshenker, B. G.
    Paul, F.
    Kim, H-J
    Aktas, O.
    Hartung, H-P
    Drappa, J.
    Smith, M.
    Rees, W. A.
    She, D.
    Katz, E.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 152 - 153
  • [39] DILTIAZEM IN HYPERTENSION - A PLACEBO-CONTROLLED STUDY
    WALKER, SD
    SKALLAND, ML
    MCGRAW, BF
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 39 (02) : 234 - 234
  • [40] A randomised, double-blind, placebo-controlled, multi-centre trial to evaluate the safety and efficacy of eculizumab in patients with relapsing neuromyelitis optica: the PREVENT study
    Wingerchuk, D. M.
    Palace, J.
    Cavus, I.
    O'Brien, F.
    Pittock, S. J.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 759 - 759
12345